AZN-BMY $400B Merger Denied: 'No Deal, Never Was,' Says Source

A senior source close to the matter told Reuters on August 5 that there were “no discussions” between AstraZeneca (AZN) and Bristol Myers Squibb (BMY) over a potential merger, denying the Financial Times’ August 2 report that triggered three days of wild speculation across global pharma markets.

“There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there are no discussions between the companies,” the source said. A second person familiar with the matter confirmed no talks are currently active. Both companies declined to comment.

AZN shares closed at $161.50 on August 5, recovering roughly 6% after falling 9% on the initial August 2 merger report. BMY fell 3.4% to $63.63, surrendering the acquisition premium built into the stock when the rumor surfaced. The combined market cap of the two companies is roughly $370 billion.

The market’s reaction tells a clear story: investors prefer AstraZeneca’s organic oncology growth over a messy cross-border megamerger with antitrust risk. The company’s antibody-drug conjugate franchise has become one of the industry’s most valuable pipelines. Enhertu, co-developed with Daiichi Sankyo, generated $3.9 billion in 2025. Datopotamab deruxtecan targets TROP2-expressing tumors, and the next-generation sonesitatug vedotin is in Phase 3 across multiple solid tumors. Shareholders do not want this pipeline diluted by a $400 billion integration that would require years of regulatory review and portfolio rationalization.

For Bristol Myers, the episode is more complicated. The company is facing patent expirations on Eliquis (2027) and Revlimid (already generic) while trying to prove that its Celgene-derived pipeline of Celmods, psychiatry assets, and cell therapies can generate enough growth to offset the losses. BMY generated roughly $48 billion in 2025 revenue, but the patent cliff timelines mean the company must replace an estimated $15 billion in annual sales over the next three to five years. BMY trades at roughly 8 times forward earnings, a valuation that reflects the market’s skepticism about the post-patent-cliff growth story. The denial removes the acquisition premium but also refocuses attention on whether BMY can generate pipeline catalysts to justify a standalone future.

What to watch next: each company’s independent execution. The swift denial, just three days from rumor to kill, leaves both management teams under pressure to deliver the catalysts that justify staying independent. For AZN, that means Phase 3 readouts across its ADC portfolio. For BMY, it is proof that the post-Revlimid growth strategy works without a partner.